PET Scanners Market to reach USD 4.9 Billion by 2032, and grow at a CAGR of 7.7%.

PET scanning has become a critical tool in the war against breast cancer, providing critical data on the extent of disease and response to treatment and, thus, substantially influencing the treatment of patients. In particular, PET scanning is critical in the staging of the disease: it is the only method for accurately assessing the size and location of the primary tumor, the extent of involvement of lymph node tissues, and the number of distant metastases. This is crucial for the determination of the stage of the disease and, thus, for the decision about the kind of intervention that would be most appropriate. At the same time, PET scanning is also a vital tool in the monitoring of the disease response to treatment: it is capable of detecting even the most subtle changes in the rates of tumor uptake of glucose, which indicates the effectiveness of chemotherapy or radiotherapy or the presence of resistance to either.